EuroBiotech—More articles of note

Newspapers

> Amal Therapeutics raised €8 million in a series B round. Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund teamed up to put together the round, which sets Amal up to move its colorectal cancer vaccine through to clinical proof of concept. Statement

> A phase 3 trial of Circassia’s Duaklir met its primary endpoints. The AstraZeneca-partnered COPD candidate deliver statistically significant improvements in lung function over its constituent active ingredients, aclidinium and formoterol, as monotherapies. Release 

> The FDA opened the door to Faron Pharmaceuticals filing for approval of Traumakine using data from trials conducted in Europe and Japan. Faron is developing Traumakine as a treatment for acute respiratory distress syndrome. Statement 

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> Summit Therapeutics posted top-line data from a phase 2 trial of its Clostridium difficile candidate. The exploratory trial showed ridinilazole reduced levels of the bacteria, although Summit is yet to provide a close look at the data. As importantly, ridinilazole had less effect on other types of bacteria than existing narrow-spectrum antibiotic fidaxomicin. Release

> Anergis reported top-line results from a phase 2b trial of its birch pollen allergy candidate. The trial met its primary endpoint of improvement on a composite symptom and medication score. Statement 

> Synairgen outlined plans to move LOXL2 inhibitor PXS-5382A into the clinic. The British biotech plans to post phase 1 data in mid-2018, at which point it will look to offload the drug to a bigger company. Synairgen’s interest in an early deal reflects its belief PXS-5382A could treat multiple major conditions, including NASH. Release